REDWOOD CITY, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on development…
– IND application cleared within 6 months of in-licensing CABA-201 binder – – CABA-201 data package and experience from prior…
REDWOOD CITY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on…
– Company expecting Investigational New Drug (IND) clearance in the first half of 2023 for CABA-201, a 4-1BB-containing fully human…
REDWOOD CITY, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on…
Both Fanconi Anemia patients treated with briquilimab successfully engrafted with neutrophil engraftment within 11 days100% total donor chimerism was achieved…
Oral Presentation, Abstract #59: 12 out of 12 AML in complete remission patients with full 1-year follow-up achieved successful neutrophil…
LAFAYETTE, La., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Viemed Healthcare, Inc. (the “Company” or “Viemed”) (NASDAQ:VMD and TSX:VMD.TO), a national…
Disc will obtain exclusive rights to MWTX-003 and other novel anti-TMPRSS6 antibodies in the United States, Europe and other territories…
VANCOUVER, BC, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN), a…